This search looks for keywords in all of the website’s content. Search tips
Filter by
EventHumanClinical trialsQuality of medicinesResearch and development
During the 2020-23 COVID-19 public health emergency, the European Medicines Agency (EMA) provided guidance for medicine developers and pharmaceutical companies to help speed up development and approval for COVID-19 medicines and address regulatory challenges arising from the pandemic.
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific advice
European Union (EU) pharmaceutical legislation known as the Clinical Trials Regulation entered into application on 31 January 2022. It aims to ensure the EU offers an attractive and favourable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants.
HumanClinical trialsRegulatory and procedural guidanceResearch and development
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific adviceVaccines
Press releaseHumanCOVID-19Clinical trialsQuality of medicinesResearch and developmentVaccines
Press releaseHumanCOVID-19Clinical trialsMedicinesResearch and development
NewsHumanCOVID-19Clinical trialsResearch and development
Press releaseHumanCOVID-19Clinical trialsResearch and developmentVaccines
EventHumanClinical trialsResearch and development